Myopia Control in the Pediatric Population: a Comparison of MiSight, Naturalvue Multifocal, and Atropine 0.05%
Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best practices for myopia control in pediatric patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 12
Healthy Volunteers: f
View:
• Children age of 5-12 years old at their baseline exam
• Children with a spherical equivalent refractive error of +0.50D (minimal hyperopia) to -7.50 D (high myopia)
• Gestational age ≥ 32 weeks.
• Birth weight \>1500g.
Locations
United States
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING
Chicago
Contact Information
Primary
Chia-Ching Wu, MS
chwu@luriechildrens.org
3122274202
Backup
Hanta Ralay Ranaivo, PhD
hralay@luriechildrens.org
3122276719
Time Frame
Start Date: 2023-05-02
Estimated Completion Date: 2026-03-13
Participants
Target number of participants: 348
Treatments
No_intervention: Observation
No treatment.
Other: Atropine
0.05% atropine. One drop per eye per day for 2 years.
Other: MiSight contact lenses
MiSight contact lenses. Daily wear for 2 years.
Related Therapeutic Areas
Sponsors
Leads: Ann & Robert H Lurie Children's Hospital of Chicago